Stocks and Investing
Stocks and Investing
Thu, February 20, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Eric Joseph Maintained (AKBA) at Buy with Increased Target to $13 on, Feb 20th, 2020
Eric Joseph of JP Morgan, Maintained "Akebia Therapeutics, Inc." (AKBA) at Buy with Increased Target from $10 to $13 on, Feb 20th, 2020.
Eric has made no other calls on AKBA in the last 4 months.
There is 1 other peer that has a rating on AKBA. Out of the 1 peers that are also analyzing AKBA, 0 agree with Eric's Rating of Hold.
This is the rating of the analyst that currently disagrees with Eric
- Ed Arce of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $16 on, Monday, November 18th, 2019